DOP2011000044A - Metodos para tratar la talasemia - Google Patents
Metodos para tratar la talasemiaInfo
- Publication number
- DOP2011000044A DOP2011000044A DO2011000044A DO2011000044A DOP2011000044A DO P2011000044 A DOP2011000044 A DO P2011000044A DO 2011000044 A DO2011000044 A DO 2011000044A DO 2011000044 A DO2011000044 A DO 2011000044A DO P2011000044 A DOP2011000044 A DO P2011000044A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- treat
- talasemia
- methods
- thalassemia
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En Ia presente invención se proporciona un método para tratar, mejorar, o retrasar aI menos un síntoma de un trastorno sanguíneo genético, por ejemplo, anemia drepanocítica o talasemia, en un paciente que lo necesite, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2. También se proporciona en parte un método para reducir un bazo dilatado en un paciente que padece talasemia, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8623308P | 2008-08-05 | 2008-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000044A true DOP2011000044A (es) | 2011-04-30 |
Family
ID=41581108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000044A DOP2011000044A (es) | 2008-08-05 | 2011-02-03 | Metodos para tratar la talasemia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110269721A1 (es) |
| EP (1) | EP2355827A2 (es) |
| JP (1) | JP2011530517A (es) |
| KR (1) | KR20110053347A (es) |
| CN (1) | CN102112131A (es) |
| AU (1) | AU2009279825A1 (es) |
| BR (1) | BRPI0917575A2 (es) |
| CA (1) | CA2732791A1 (es) |
| CL (1) | CL2011000242A1 (es) |
| CO (1) | CO6351728A2 (es) |
| CR (1) | CR20110115A (es) |
| DO (1) | DOP2011000044A (es) |
| EC (1) | ECSP11010847A (es) |
| IL (1) | IL211061A0 (es) |
| MA (1) | MA32611B1 (es) |
| MX (1) | MX2011001426A (es) |
| NI (1) | NI201100031A (es) |
| RU (1) | RU2011108563A (es) |
| SV (1) | SV2011003823A (es) |
| WO (1) | WO2010017122A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
| WO2006024034A1 (en) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| EP1951684B1 (en) | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| WO2012071612A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| PT3409278T (pt) | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de proteína cinase heterocíclicos |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| CN103664799A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CA2905993C (en) * | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| TW202134236A (zh) | 2014-06-12 | 2021-09-16 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| SI3442947T1 (sl) * | 2016-04-15 | 2023-10-30 | Epizyme, Inc. | Z aminom substituirane arilne ali heteroarilne spojine kot inhibitorji ehmt1 in ehmt2 |
| WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | COMBINATION THERAPIES WITH EHMT2 INHIBITORS |
| EP3697420A4 (en) * | 2017-10-18 | 2021-11-24 | Epizyme, Inc. | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES |
| BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| CN112778282B (zh) * | 2021-01-06 | 2022-07-22 | 温州医科大学 | 一种嘧啶类小分子化合物及其应用 |
| WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1951684B1 (en) * | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
-
2009
- 2009-08-03 BR BRPI0917575A patent/BRPI0917575A2/pt not_active IP Right Cessation
- 2009-08-03 WO PCT/US2009/052544 patent/WO2010017122A2/en active Application Filing
- 2009-08-03 EP EP09741504A patent/EP2355827A2/en not_active Withdrawn
- 2009-08-03 KR KR1020117005224A patent/KR20110053347A/ko not_active Application Discontinuation
- 2009-08-03 US US13/057,133 patent/US20110269721A1/en not_active Abandoned
- 2009-08-03 AU AU2009279825A patent/AU2009279825A1/en not_active Abandoned
- 2009-08-03 CA CA2732791A patent/CA2732791A1/en not_active Abandoned
- 2009-08-03 CN CN2009801303954A patent/CN102112131A/zh active Pending
- 2009-08-03 JP JP2011522136A patent/JP2011530517A/ja active Pending
- 2009-08-03 MX MX2011001426A patent/MX2011001426A/es not_active Application Discontinuation
- 2009-08-03 RU RU2011108563/15A patent/RU2011108563A/ru not_active Application Discontinuation
-
2011
- 2011-02-01 SV SV2011003823A patent/SV2011003823A/es not_active Application Discontinuation
- 2011-02-02 NI NI201100031A patent/NI201100031A/es unknown
- 2011-02-03 IL IL211061A patent/IL211061A0/en unknown
- 2011-02-03 DO DO2011000044A patent/DOP2011000044A/es unknown
- 2011-02-04 CL CL2011000242A patent/CL2011000242A1/es unknown
- 2011-02-28 EC EC2011010847A patent/ECSP11010847A/es unknown
- 2011-03-02 CR CR20110115A patent/CR20110115A/es not_active Application Discontinuation
- 2011-03-04 MA MA33672A patent/MA32611B1/fr unknown
- 2011-03-04 CO CO11026653A patent/CO6351728A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011001426A (es) | 2011-03-21 |
| NI201100031A (es) | 2011-09-26 |
| ECSP11010847A (es) | 2011-07-29 |
| CN102112131A (zh) | 2011-06-29 |
| WO2010017122A3 (en) | 2010-04-08 |
| CO6351728A2 (es) | 2011-12-20 |
| JP2011530517A (ja) | 2011-12-22 |
| EP2355827A2 (en) | 2011-08-17 |
| US20110269721A1 (en) | 2011-11-03 |
| WO2010017122A2 (en) | 2010-02-11 |
| KR20110053347A (ko) | 2011-05-20 |
| SV2011003823A (es) | 2011-08-15 |
| MA32611B1 (fr) | 2011-09-01 |
| RU2011108563A (ru) | 2012-09-10 |
| AU2009279825A1 (en) | 2010-02-11 |
| CA2732791A1 (en) | 2010-02-11 |
| CL2011000242A1 (es) | 2011-04-08 |
| CR20110115A (es) | 2011-06-03 |
| IL211061A0 (en) | 2011-04-28 |
| BRPI0917575A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000044A (es) | Metodos para tratar la talasemia | |
| CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| EP2581092A4 (en) | AGENT IMPROVING THE METABOLISM OF LIPIDS | |
| MX2012010418A (es) | Inhibidores syk de imidazopiridinas. | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
| WO2009124294A3 (en) | Pharmaceutical compositions for binding sphingosine-1-phosphate | |
| UA102097C2 (ru) | Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17 | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| WO2008031835A3 (en) | Method of treating autoimmune diseases using vegf-pathway inhibitors | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| BR112014000889A2 (pt) | tratamento para hipoxia | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease |